Acarbose (prescription α-glucosidase inhibitor) — evidence review — Intervention & Protocol Data

What we know

Label-derived facts remain separate from AI-generated context.

No label facts are available for this entry yet.

No AI context is available yet.

Community-supplied references. Check the linked source before relying on a claim.

Practical details pulled from scanned or cited interventions.

**Lower postprandial glucose (and HbA1c) in type 2 diabetes** (approved use).
**Delay / prevention of type 2 diabetes in impaired glucose tolerance** (STOP-NIDDM claim; not an aging claim).
**Cardiovascular-event reduction in IGT** (STOP-NIDDM secondary / JAMA 2003 claim).
**Human lifespan extension / delayed aging** (longevity claim).
**Human healthspan / delayed multimorbidity of aging in people without diabetes** (longevity claim).
**Mouse lifespan / healthspan** (preclinical; often presented as if it were human).
**Modest weight loss** (secondary / community claim).
**Better exercise or “metabolic longevity” in insulin-sensitive adults** (community claim).

Dose, timing, and brands from 1 public protocol. Private and hidden usage is excluded.

Where this intervention appears and what it tends to sit beside.